CorMedix Inc
CRMD14.350USD
+0.210+1.49%
종가 08/28, 16:00（ET）시세는 15분 지연됩니다
1.07B시가총액
62.33P/E TTM
자세한 내용은 CorMedix Inc 회사
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
회사 정보
종목 코드 CRMD
회사 이름CorMedix Inc
상장일Mar 25, 2010
CEOMr. Joseph Todisco
직원 수64
유형Ordinary Share
회계 연도 종료Mar 25
주소300 Connell Drive
도시BERKELEY HEIGHTS
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호07922
전화19085179500
웹사이트https://cormedix.com/
종목 코드 CRMD
상장일Mar 25, 2010
CEOMr. Joseph Todisco
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Joseph Todisco
Mr. Joseph Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
323.43K
-2.01%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-3.77%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
53.47K
-31.86%
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
11.00K
-69.44%
Mr. Dan Ferry
Mr. Dan Ferry
IR Contact Officer
IR Contact Officer
--
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth (Liz) Massonhurlburt
Ms. Elizabeth (Liz) Massonhurlburt
Executive Vice President, Chief Clinical Strategy and Operations Officer
Executive Vice President, Chief Clinical Strategy and Operations Officer
--
--
Dr. Matthew T. (Matt) David, M.D.
Dr. Matthew T. (Matt) David, M.D.
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ms. Beth Zelnick Kaufman
Ms. Beth Zelnick Kaufman
Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary
Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Joseph Todisco
Mr. Joseph Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
323.43K
-2.01%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-3.77%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
53.47K
-31.86%
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
11.00K
-69.44%
Mr. Dan Ferry
Mr. Dan Ferry
IR Contact Officer
IR Contact Officer
--
--
수익 분석
FY2025Q1
FY2024
데이터 없음
지역별USD
이름
수익
비율
United States
39.08M
0.00%
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sat, Aug 16
마지막 업데이트: Sat, Aug 16
주주
주주 유형
주주
주주
비율
BlackRock Institutional Trust Company, N.A.
6.42%
Abdalkader (Shaibatalhamd Aymen)
6.22%
The Vanguard Group, Inc.
5.77%
Marshall Wace LLP
3.46%
Citadel Advisors LLC
2.30%
기타
75.83%
주주
주주
비율
BlackRock Institutional Trust Company, N.A.
6.42%
Abdalkader (Shaibatalhamd Aymen)
6.22%
The Vanguard Group, Inc.
5.77%
Marshall Wace LLP
3.46%
Citadel Advisors LLC
2.30%
기타
75.83%
주주 유형
주주
비율
Investment Advisor
22.34%
Investment Advisor/Hedge Fund
13.04%
Hedge Fund
8.73%
Individual Investor
7.30%
Research Firm
1.48%
Sovereign Wealth Fund
1.26%
Pension Fund
0.63%
Bank and Trust
0.28%
Venture Capital
0.06%
기타
44.87%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
280
26.40M
35.51%
-7.69M
2025Q1
281
29.73M
44.27%
-179.25K
2024Q4
252
24.74M
40.82%
-30.08K
2024Q3
228
19.79M
34.25%
-1.78M
2024Q2
217
17.74M
32.28%
-4.09M
2024Q1
218
17.92M
32.60%
-5.73M
2023Q4
217
19.38M
35.35%
-2.82M
2023Q3
208
18.46M
33.68%
-3.54M
2023Q2
197
19.74M
38.10%
+6.18M
2023Q1
190
11.28M
25.34%
-2.76M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
BlackRock Institutional Trust Company, N.A.
4.31M
5.8%
+109.81K
+2.61%
Mar 31, 2025
The Vanguard Group, Inc.
3.63M
4.89%
+255.97K
+7.58%
Mar 31, 2025
Marshall Wace LLP
230.53K
0.31%
+230.53K
--
Mar 31, 2025
State Street Global Advisors (US)
1.54M
2.07%
+85.97K
+5.92%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.43M
1.93%
+40.10K
+2.88%
Mar 31, 2025
Norges Bank Investment Management (NBIM)
940.59K
1.27%
+940.59K
--
Dec 31, 2024
더 보기
관련 ETF
마지막 업데이트: Wed, Aug 6
마지막 업데이트: Wed, Aug 6
이름
비율
Invesco Dorsey Wright Healthcare Momentum ETF
1.62%
SPDR S&P Pharmaceuticals ETF
1.31%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.81%
First Trust Active Factor Small Cap ETF
0.41%
Vanguard US Momentum Factor ETF
0.21%
iShares Micro-Cap ETF
0.18%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.09%
iShares Biotechnology ETF
0.08%
Invesco Nasdaq Biotechnology ETF
0.08%
더 보기
Invesco Dorsey Wright Healthcare Momentum ETF
비율1.62%
SPDR S&P Pharmaceuticals ETF
비율1.31%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
비율0.81%
First Trust Active Factor Small Cap ETF
비율0.41%
Vanguard US Momentum Factor ETF
비율0.21%
iShares Micro-Cap ETF
비율0.18%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
비율0.09%
ProShares Ultra Nasdaq Biotechnology
비율0.09%
iShares Biotechnology ETF
비율0.08%
Invesco Nasdaq Biotechnology ETF
비율0.08%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
